Tag: Progressive multifocal leukoencephalopathy

Infusion reactions affect 34% to 40% of patients receiving their first ocrelizumab infusion, raising questions about its safety and whether ocrelizumab is hazardous. This article addresses the common side effects and rare but serious risks associated with this multiple sclerosis medication.

Up to 85% of the general adult population carries the John Cunningham (JC) virus, which is typically harmless. However, for those on specific immunomodulating drugs, understanding 'What medication can cause PML?' is vital, as these drugs can reactivate the virus, leading to this serious brain disease.

Progressive Multifocal Leukoencephalopathy (PML) is a rare but serious brain infection caused by the reactivation of the John Cunningham (JC) virus [1.10.2]. This article explores a critical question for many patients: **what drugs increase the risk of PML?**

According to a study published in *Molecules*, memory impairment was one of the most frequently reported neurological side effects associated with the JAK inhibitors ruxolitinib (Jakafi) and tofacitinib. While Jakafi does not commonly cause memory loss, patients have reported cognitive issues, and in very rare, serious cases, it is linked to a severe brain infection called progressive multifocal leukoencephalopathy (PML), which can manifest with memory problems and confusion.